OOS Investigations: Decision-Making in Practice and FDA Expectations
How to interpret results, recognize signals, and align investigation decisions with current FDA expectations for 2026.
OOS results test more than the laboratory.
OOS results require disciplined decisions from the first assessment, because early interpretation often determines whether the investigation remains credible and complete. This session structures OOS evaluation pathways, helping teams interpret results, expand inquiries appropriately, and document conclusions with consistent scientific reasoning.
The session follows the investigation sequence from initial result review through cause evaluation and final documentation. It distinguishes how laboratory findings, process signals, and broader quality indicators are weighed, then clarifies when escalation is warranted and how current FDA expectations shape each decision point.
This session takes a closer look at how OOS investigations unfold in practice, from the moment a result is identified to the way conclusions are formed and documented.
Through practical discussion, the focus is on interpreting results with clarity, recognizing when deeper evaluation is needed, and aligning investigation decisions with current FDA expectations.
What the session works through
A practical walkthrough of how OOS investigations actually unfold, and where decisions are most often challenged.
How OOS results are initially assessed and why early decisions often shape the entire investigation
Recognizing meaningful signals, trends, and inconsistencies that may not be immediately obvious
Approaches to evaluating laboratory error versus potential process-related causes
How investigation pathways are structured, including when to expand beyond the laboratory
Documentation practices that reflect clear thinking, scientific reasoning, and consistent decision-making
FDA expectations for OOS investigations, including key principles from 21 CFR Part 211 and related guidance
Designed for professionals responsible for result assessment, investigation oversight, and quality decisions that must withstand regulatory review.
Led by a 30-year regulated industries specialist
Meredith Crabtree
Meredith Crabtree has over 30 years of experience in regulated industries, spanning Blood, Plasma, Tissue, Laboratory, Pharma, Medical Device, Cosmetics, Supplements, and Animal Health, including manufacturing, packaging, labelling, and distribution operations. She is a Quality Consultant specializing in product label reviews, third party inspections, Consent Decree and Recall support, and performs regulatory assessments and quality trainings.
Reserve your place for July 17, 2026
A focused, practice-based session on OOS investigation decisions and current FDA expectations, for teams who need clarity, not theory.
Register for This Webinar